knowledge -WSS

knowledge

author：explore 2025-09-27 09:54:57 - browse：33

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Cholera vaccine supplies dangerously low, outbreaks surging

hotspot

WSS

Plastic surgeons increase patient psychiatric screenings

Are embryos people? Reproductive medicine's future depends on the answer

Are embryos people? Reproductive medicine's future depends on the answer

Pfizer is about to make a big push in cancer. Will investors listen?

2016年8月，明仁天皇发表视频讲话表示，自己由于身体原因，很难继续履行职责。

Are embryos people? Reproductive medicine's future depends on the answer

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

STAT Madness 2024: Meet the contenders

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Heart attack and stroke risk calculators need revising

Cholera vaccine supplies dangerously low, outbreaks surging

After affirmative action ruling, medical educators look to 'holistic review'

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Malaria cases in Florida and Texas: Here’s what you need to know

Methadone treatment changes are coming. Do they go far enough?

leisure time

Plastic surgeons increase patient psychiatric screenings

Nurses recount patients attacks

Neuroscience renaissance leads to new crop of psychiatric drugs

UnitedHealth increases loan offers after Change Healthcare outage

Using force crossed my mind when examining a defiant young patient

Neuroscience’s long legacy of racism

knowledge

Wikipedia

hotspot

Wikipedia